Trial Profile
The change of retinal sensitivity with intravitreal injection of aflibercept for wet type of age-related macular degeneration.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Apr 2019
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 28 Mar 2019 Status changed from active, no longer recruiting to completed.
- 25 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 14 Dec 2017 Status changed from not yet recruiting to recruiting.